

* * * * * Judy,

please do not
include *

Appl. No. 09/889,300

AMENDMENTS TO THE CLAIMS

- amend 7
1. (Currently Amended) A pharmaceutical composition for treatment of cancer disease comprising a ~~first~~ antibody directed against the cellular membrane antigen Ep-CAM and at least one ~~vaccine~~ adjuvant, wherein said first antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO: 1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Currently Amended) The pharmaceutical composition of ~~any one of claims 1-3~~ claim 1, wherein said first antibody has the same specificity of binding as that antibody defined in claim [4]1.

6. (Previously Presented) The pharmaceutical composition of claim 1, further comprising at least a second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.

2

7. (Previously Presented) The pharmaceutical composition of claim 1, wherein said ~~first~~ antibody is contained in a dosage range of 0.01 – 4 mg.

3

8. (Previously Presented) A method of treating cancer disease comprising administering to a patient in need thereof the pharmaceutical composition of claim 1.

Appl. No. 09/889,300

⁴
~~9.~~ (Previously Presented) The method according to claim ³~~8~~, wherein said pharmaceutical composition is administered by subcutaneous, intradermal or intramuscular injection.

10. (Canceled)

11. (Cancelled)

⁵
~~12.~~ (Currently Amended) The method of claim ³~~8~~ or ⁴~~10~~ wherein said ~~first~~ antibody is administered at a dosage in the range of 0.01 to 4 mg antibody.

13. (Canceled)

⁶
~~14.~~ (Previously Presented) The method according to claim ⁵~~12~~ wherein said dosage is 0.5 mg antibody.